ACE ImmunoID for Mutational Burden
Discovering the key to beneficial patient response
Checkpoint inhibitors and immune modulators have demonstrated great promise in the battle against cancer, but even still, only a small percentage of patients show sustained response to immunotherapy. While the pace of immuno-oncology research is gaining momentum, the continued advancement of immunotherapy requires a new approach for the selection of the most promising pathways and the identification of the patients who are most likely to demonstrate beneficial response.
The development of effective immunotherapies
Personalis has developed an end-to-end solution for the discovery and the development of immune checkpoint modulators, ACE ImmunoID for Mutational Burden, consisting of analytically-validated assays optimized for immuno-oncology:
- ACE Cancer Exome
- ACE Extended Cancer Panel for DNA
Where standard sequencing methods have gaps in coverage that can result in false positive results, incomplete tumor characterization, and unreliable mutational burden assessment, our proprietary ACE (Accuracy and Content Enhanced) technology augments sequencing gaps for a greater degree of confidence in your genomic data.
ACE Cancer Exome
The ACE Cancer Exome provides coverage of >20,000 genes with enhanced coverage of >1,400 cancer-related genes, for more accurate mutational burden assessment. STK11 is a tumor suppressor gene, and is the most mutated gene in lung adenocarcinoma. Figure 1 illustrates the superior, uniform coverage of exonic regions at 12G with the ACE Cancer Exome (blue plus green) compared to the most widely used standard exome (blue only), and is an example of the high accuracy, high coverage sequencing provided by our assay.
Figure 1. STK11 gene showing enhanced coverage using the ACE Cancer Exome.
ACE Extended Cancer Panel for DNA
The ACE Extended Cancer Panel for DNA provides high depth, high accuracy coverage of >1,400 cancer-related genes including DNA repair and replication pathways and GC-rich content. The first of its kind, our panel provides more coverage of gene pathways and functions known to be involved in cancer biology, including clinically-relevant genes, key cancer pathway genes, and consensus driver genes.
The below sequencing plots highlight superior, uniform coverage using the ACE Extended Cancer panel for DNA analysis. Isoforms of PI3 Kinase (PIK3CD and PIK3R3) and critical downstream signaling molecules such as BAD (survival), NFKB1 (inflammatory response), and many others are covered by the ACE Platform, yet not included in standard cancer panels.
Figure 2. ACE sequencing coverage of genes within the PI3 Kinase pathway of action.
Ready to accelerate the development of your immune checkpoint modulators?
Learn more about how we can transform immuno-oncology clinical development together, complete the form above or contact us at firstname.lastname@example.org.